Home Alzheimer’s Disease Venetoclax with Azacytidine Improved Overall Survival for Patients with AML

Venetoclax with Azacytidine Improved Overall Survival for Patients with AML

Venetoclax (Venclexta) in combination with azacytidine met its dual primary endpoints of overall survival and composite complete remission rate in a phase III VIALE-A study, according to a Genentech press release.

The combination showed a statistically significant improvement in overall survival for people with previously untreated acute myeloid leukemia, who were also ineligible for intensive induction chemotherapy. The results were significant compared to treatment with azacytidine, a hypomethylating agent, alone.

“Acute myeloid leukemia remains a challenging blood cancer, with particularly low median survival rates in patients who cannot tolerate intensive chemotherapy given their age or underlying health,” Levi Garraway, MD, PhD, chief medical officer and head of global product development said in a press release. “These data validate the benefit that this Venclexta-based…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Recent Comments